Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to HSCT, however in Europe it is only approved for patients who are not eligible for HSCT.

Voso, M.T., Leone, G., Piciocchi, A., Fianchi, L., Santarone, S., Candoni, A., et al. (2017). Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. ANNALS OF ONCOLOGY, 28(7), 1547-1553 [10.1093/annonc/mdx154].

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study

VOSO, MARIA TERESA;
2017

Abstract

Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to HSCT, however in Europe it is only approved for patients who are not eligible for HSCT.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - Malattie del Sangue
English
Con Impact Factor ISI
allogeneic stem-cell transplantation; azacitidine; high-risk MDS; hypomethylating treatment
Voso, M.T., Leone, G., Piciocchi, A., Fianchi, L., Santarone, S., Candoni, A., et al. (2017). Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. ANNALS OF ONCOLOGY, 28(7), 1547-1553 [10.1093/annonc/mdx154].
Voso, Mt; Leone, G; Piciocchi, A; Fianchi, L; Santarone, S; Candoni, A; Criscuolo, M; Masciulli, A; Cerqui, E; Molteni, A; Finelli, C; Parma, M; Poloni, A; Carella, A; Spina, F; Cortelezzi, A; Salvi, F; Alessandrino, E; Rambaldi, A; Sica, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Voso et al, Ann Oncol 2017.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 2.98 MB
Formato Adobe PDF
2.98 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/187795
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 36
social impact